Direct Patient Reporting in the European Union
Pharmacovigilance legislation has expanded adverse drug reaction reporting by patients in the European Union. But to maximise its benefits, appropriate reporting systems must be in place. In this new publication, we describe and analyse direct patient reporting systems in seven EU member States—and provide recommendations to improve them. Click here to read the report.
Seven ways the EU could improve access to medicines and biomedical innovation
The European Union’s free trade and R&D policies promote excessive intellectual property protection. This approach jeopardises access to affordable, needed medicines and impedes needs-driven biomedical innovation. HAI Europe, the Médecins Sans Frontières Access Program and Oxfam have developed a set seven recommendations that could improve access to medicines and biomedical innovation in Europe and around the world.
Trading Away Access to Medicines (Revisited) – Report from HAI Europe and Oxfam
A new report by HAI Europe and Oxfam has found that the European Commission is putting the interests of multinational drug companies above those of millions of people with no access to affordable life-saving medicines. The lack of a widely accessible treatment for Ebola, as well as the high price of Hep-C and cancer medicines, show that it's time for the Commission to rethink its trade and innovation policies. Also see our press release.
Investor-to-state dispute settlement in EU-US trade agreement risks access to affordable medicines
HAI Europe, along with several other European and American NGOs, publicly criticised the inclusion of 'investor-to-state dispute settlement' in the Transatlantic Trade and Investment Partnership (TTIP), warning that it will undermine public health policies of European Union Member States and severely jeopardise access to affordable medicines and public health protection. To learn more, read our joint press release and response to the European Commission's public consultation on the issue.